ELUTIA INC. Form 8-K Summary
Business Context and Reporting Period
Elutia Inc. (ELUT), an emerging growth company incorporated in Delaware, filed this Current Report on February 3, 2025. The filing provides preliminary net sales estimates for the fiscal year ended December 31, 2024, while the company finalizes its annual closing procedures. The company operates in the medical device sector with product lines in device protection, women's health, and cardiovascular solutions.
Key Financial Metrics
The filing provides preliminary net sales data but does not disclose profit, cash flow, margins, debt, or liquidity metrics for the period.
| Product Segment | 2024 Preliminary Sales ($000s) | 2024 % of Sales | 2023 Sales ($000s) | 2023 % of Sales | Change ($000s) | Change (%) |
|---|---|---|---|---|---|---|
| Device Protection | 9,905 | 41% | 9,401 | 38% | 504 | 5% |
| Women's Health | 11,554 | 47% | 10,304 | 42% | 1,250 | 12% |
| Cardiovascular | 2,916 | 12% | 5,040 | 20% | (2,124) | (42%) |
| Total Net Sales | 24,375 | 100% | 24,745 | 100% | (370) | (1%) |
Note: The filing text does not provide clear values for net income, operating cash flow, gross margins, total debt, or liquidity positions.
Material Changes vs. Prior Period
- Total Revenue: Preliminary net sales decreased by $370,000 (1%) compared to 2023.
- Women's Health: This segment drove growth, increasing sales by $1.25 million (12%) and expanding its share of total revenue from 42% to 47%.
- Cardiovascular: This segment experienced a significant decline, with sales dropping by $2.124 million (42%), reducing its revenue share from 20% to 12%.
- Device Protection: Sales increased modestly by $504,000 (5%).
Guidance, Outlook, and Risks
Management Commentary: The company is in the process of finalizing its 2024 results. The preliminary figures are unaudited and subject to adjustment upon completion of closing procedures. Final results will be reported in the Form 10-K.
Risks and Contingencies: The filing highlights several material risks, including:
- Going Concern: Uncertainty regarding the ability to continue as a going concern and achieve profitability.
- Legal Litigation: Ongoing lawsuits and claims related to recalled FiberCel and other viable bone matrix products.
- Commercialization: Dependence on the successful commercialization of the newly approved EluPro product.
- Supply Chain: Reliance on a limited number of third-party suppliers and manufacturers.
- Regulatory and IP: Risks associated with obtaining regulatory approvals and protecting intellectual property.
Forward-Looking Statements: The company disclaims any obligation to update forward-looking statements and warns that actual results may differ materially due to known and unknown risks.
Investor Verification Checklist
- Verify the final audited net sales figures in the upcoming Form 10-K for the year ended December 31, 2024.
- Review the company's liquidity position and cash burn rate to assess the "going concern" risk mentioned in the filing.
- Monitor the status of litigation regarding recalled FiberCel products and potential financial impacts.
- Track the commercial performance and market adoption of the EluPro product.
- Confirm the reasons behind the 42% decline in the Cardiovascular segment.